Literature DB >> 15559489

Stability of drug additives in peritoneal dialysis solutions in a new container.

Markus Voges1, Dirk Faict, Guy Lechien, Michel Taminne.   

Abstract

OBJECTIVE: To evaluate the stability of gentamicin, tobramycin, netilmycin, vancomycin, cefazolin, unfractionated heparin, and low molecular weight heparin when added to four different peritoneal dialysis (PD) solutions [Extraneal (Baxter Healthcare, Castlebar, Ireland); Physioneal, Nutrineal, and Dianeal (Baxter Healthcare, Grosotto, Italy)] in new, non-PVC Clear-Flex containers. MEASUREMENTS: Gentamicin, tobramycin, netilmycin, vancomycin, cefazolin, unfractionated heparin, and low molecular weight heparin were injected into separate bags of PD solution. Samples were withdrawn at predefined sampling times and the concentration of each drug was analyzed using high-performance liquid chromatography (for gentamicin, tobramycin, vancomycin, and cefazolin), or bioassay (for netilmycin, gentamicin, and tobramycin in Nutrineal), or coagulation methods (heparins).
RESULTS: Netilmycin, vancomycin, cefazolin, and heparin in Physioneal, Nutrineal, Extraneal, and Dianeal were stable for at least 24 hours at 25 degrees C and for an additional 4 hours at 37 degrees C. Gentamicin in Nutrineal, Extraneal, and Dianeal was stable for at least 24 hours at 25 degrees C and for an additional 4 hours at 37 degrees C; gentamicin in Physioneal was stable for less than 24 hours at 25 degrees C. Tobramycin in Nutrineal and Extraneal was stable for at least 24 hours at 25 degrees C and for an additional 4 hours at 37 degrees C; tobramycin in Physioneal and Dianeal was stable for less than 24 hours at 25 degrees C.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15559489

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  6 in total

Review 1.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

2.  Stability of the combination of ceftazidime and cephazolin in icodextrin or pH neutral peritoneal dialysis solution.

Authors:  Rahul P Patel; Madhur D Shastri; Mohammad Bakkari; Troy Wanandy; Matthew D Jose
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

Review 3.  Peritoneal dialysis--current status and future challenges.

Authors:  Simon J Davies
Journal:  Nat Rev Nephrol       Date:  2013-05-21       Impact factor: 28.314

4.  Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.

Authors:  Manuel Kussmann; Linda Schuster; Sarah Wrenger; Petra Pichler; Gottfried Reznicek; Heinz Burgmann; Wolfgang Poeppl; Markus Zeitlinger; Martin Wiesholzer
Journal:  Perit Dial Int       Date:  2016-09-28       Impact factor: 1.756

5.  Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).

Authors:  Dwarakanathan Ranganathan; Saiyuri Naicker; Steven C Wallis; Jeffrey Lipman; Sharad K Ratanjee; Jason A Roberts
Journal:  Perit Dial Int       Date:  2015-10-22       Impact factor: 1.756

Review 6.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.